Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD40L interaction

Journal of Clinical Investigation

Volumn 105, Issue 11, 2000, Pages 1623-1630

  Lode, Holger N ^a   Xiang, Rong ^a   Pertl, Ursula ^a   Förster, Elisabeth ^b   Schoenberger, Stephen P ^c   Gillies, Stephen D ^d   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d Lexigen Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; GLYCOPROTEIN GP 39; INTERLEUKIN 2;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL MATURATION; CELL STIMULATION; DRUG EFFECT; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0034123555     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9177     Document Type: Article

References (41)

1. Roth, J.A., and Cristiano, R.J. 1997. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer. Inst. 89:21-39.
2. Reisfeld, R.A., Mueller, B.M., Handgretinger, R., Yu, A.L., and Gillies, S.D. 1994. Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy. Prog. Brain Res. 101:201-212.
3. Lode, H.N., Xiang, R., Becker, J.C., Gillies, S.D., and Reisfeld, R.A. 1998. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80:277-292.
4. Becker, J.C., Pancook, J.D., Gillies, S.D., Furukawa, K., and Reisfeld, R.A. 1996. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183:2361-2366.
5. Becker, J.C., Varki, N.M., Gillies, S.D., Furukawa, K., and Reisfeld, R.A. 1996. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA. 93:7826-7831.
6. Becker, J.C., Varki, N.M. Gillies, S.D., Furukawa, K., and Reisfeld, R.A. 1997. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98:2801-2804.
7. Kaplan, J.M., et al. 1999 Induction of anti-tumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol 163:699-707.
8. Babcock, B., et al. 1998. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol. Immunol. 35:1121-1133.
9. + T lymphocytes. Proc. Natl. Acad. Sci. USA. 96:2982-2987.
10. Zeh, H.J., Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A., and Yang, J.C. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo anti-tumor efficacy. J. Immunol 162:989-994.
11. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161:5500-5506.
12. Kirkin, A.F., Dzhandzhugazyan, K., and Zeuthen, J. 1998. Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS. 106:665-679.
13. + T cells in vitro. J. Exp. Med. 183:2247-2257.
14. Sprent, J. 1995. Antigen-presenting cells. Professionals and amateurs. Curr. Biol. 5:1095-1097.
15. Sprent, J. 1995. Central tolerance of T cells. Int. Rev. Immunol. 13:95-105.
16. Straten, P.T., et al. 1998. Activation of pre-existing T cell clones by targeted interleukin 2 therapy. Proc. Natl. Acad. Sci. USA. 95:8785-8790.
17. Chambers, C.A., and Allison, J.P. 1999. Co-stimulatory regulation of T cell function. Cur. Opin. Cell Biol. 11:203-210.
18. + T cells. J. Immunol. 162:3256-3262.
19. Matzinger, P. 1998. An innate sense of danger. Semin. Immunol. 10:399-415.
20. Matzinger, P. 1994. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 12:991-1045.
21. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R., and Melief, C.J. 1998. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:480-483.
22. Mackey, M.F., et al. 1998. Dendritic cells require maturation via CD40 to generate protective anti-tumor immunity. J. Immunol. 161:2094-2098.
23. Becker, J.C., Pancook, J.D., Gillies, S.D., Mendelsohn, J., and Reisfeld, R.A. 1996. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Natl. Acad. Sci. USA. 93:2702-2707.
24. Sabzevari, H., Gillies, S.D., Mueller, B.M., Pancook, J.D., and Reisfeld, R.A. 1994. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA. 91:9626-9630.
25. Haraguchi, M., et al. 1994. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. USA. 91:10455-10459.
26. Rolink, A., Melchers, F., and Andersson, J. 1996. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity. 5:319-330.
27. Noelle, R.J., et al. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA. 89:6550-6554.
28. Durie, F.H., et al. 1993. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 261:1328-1330.
29. Xiang, R., et al. 1997. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:4948-4955.
30. Xiang, R., Lode, H.N., Dreier, T., Gillies, S.D., and Reisfeld, R.A. 1998. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res. 58:3918-3925.
31. Xiang, R., Lode, H.N., Gillies, S.D., and Reisfeld, R.A. 1999. T cell memory against colon carcinoma is long lived in the absence of antigen. J. Immunol. 163:3676-3683.
32. Dolman, C.S., et al. 1998. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin. Cancer Res. 4:2551-2557.
33. Lode, H.N., et al. 1998. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood. 91:1706-1715.
34. +T cell responses in anti-tumor immunity. Curr. Opin. Immunol. 10:588-594.
35. Toes, R.E.M., Schoenberger, S.P., van der Voort, E.E., Offringa, R., and Melief, C.J.M. 1998. CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 10:443-448.
36. Schoenberger, S.P., et al. 1998. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res. 58:3094-3100.
37. Bianchi, R., et al. 1999. Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligarion. J. Immunol. 163:2517-2521.
38. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. Crit. Rev. Immunol. 18:87-98.
39. Lode, H.N., et al. 1999. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA. 96:8591-8596.
40. Diehl, L., et al. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5:774-779.
41. + T cell tolerance to T cell priming through in vivo ligation of CD40. Nat. Med. 5:780-787.